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A B S T R A C T
A hot melt 3D inkjet printing method with the potential to manufacture formulations in complex and adaptable
geometries for the controlled loading and release of medicines is presented. This ﬁrst use of a precisely con-
trolled solvent free inkjet printing to produce drug loaded solid dosage forms is demonstrated using a naturally
derived FDA approved material (beeswax) as the drug carrier and fenoﬁbrate as the drug. Tablets with bespoke
geometries (honeycomb architecture) were fabricated. The honeycomb architecture was modiﬁed by control of
the honeycomb cell size, and hence surface area to enable control of drug release proﬁles without the need to
alter the formulation. Analysis of the formed tablets showed the drug to be evenly distributed within the
beeswax at the bulk scale with evidence of some localization at the micron scale. An analytical model utilizing a
Fickian description of diﬀusion was developed to allow the prediction of drug release. A comparison of ex-
perimental and predicted drug release data revealed that in addition to surface area, other factors such as the cell
diameter in the case of the honeycomb geometry and material wettability must be considered in practical dosage
form design. This information when combined with the range of achievable geometries could allow the bespoke
production of optimized personalised medicines for a variety of delivery vehicles in addition to tablets, such as
medical devices for example.
1. Introduction
In many societies, especially those with an increasingly elderly
population there has been a signiﬁcant increase in the number of pa-
tients suﬀering from multiple chronic illnesses and hence an increase in
treatment regimens where patients are required to take many medicines
several times a day [1,2]. Such complex regimes tend to lower patient
compliance and adherence to the medicine regime. Most clinical
therapies are based on the “one drug, one dose ﬁts all” approach [3],
however, due to individual diﬀerences such as age, genetic makeup,
environmental factors and physiological body conditions, drug response
can vary in patients and hence treatment maybe suboptimal [4]. These
challenges illustrate the need for the consideration and development of
manufacturing approaches for medicines tailored for individual patient
needs. 3D printing (or additive manufacturing) has been proposed by a
number of authors as being a method that could address this situation
[5–9].
Here we demonstrate, for the ﬁrst time, the use of a 3D inkjet
printing (3DP) technique to manufacture a viable and tuneable phar-
maceutical dosage form. The use of an ink-jet approach, rather than the
more typically used extrusion [7] and powder layering approaches [10]
facilitates a spatial resolution of up to 50 μm and ability to facilitate the
co-deposition of multiple inks contemporaneously [11–13]. The high
spatial resolution is attained via the deposition of very small volumes
(picolitres) of formulation ink and oﬀers the advantage of accurate
delivery and the spatial localization of materials. These capabilities
have been exploited in life science, drug delivery and genomics [14,15].
The recent FDA approval of a 3DP powder-layered tablet SPRITAM® in
2015 [16], and recent advances in the printing of medicines with
multiple active pharmaceutical ingredients [5,6,17], have already
proven 3DP as a key technology in the manufacturing of solid dosage
forms. Hence, 3D inkjet printing could enable the delivery of accurate
doses, which is highly desirable when handling potent drugs and in the
paediatric population where the dose adjustment is required based on
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patient age, body mass and clinical conditions [18].
An additional beneﬁt of such high-resolution control of dosage form
composition is the potential customization of release proﬁles. This
would be highly desirable when managing long-term illnesses such as
hypertension and anti-depression for optimum therapeutic reasons
[19–22]. Traditionally, controlled and variable drug release is achieved
through the use of diﬀerent polymer formulations and the use of barrier
ﬁlms [23–26]. This can, however, be associated with rather complex
multi-component formulations and a burst release of the drug whereby
a high release rate is attained initially due to the dissolution of the drug
present at the surface, which may cause a negative therapeutic eﬀect
and toxicity [27]. 3D printing oﬀers an alternative route where, dosage
form geometry and hence surface area alone can be used to control drug
release from a solid matrix [28–31]. This would be a relatively
straightforward and generic way of achieving customizable release
proﬁles, but geometry control alone has limitations. For example, if we
assume that drug elution is dictated by Fickian diﬀusion through the
tablet, then if there are no changes in boundary conditions or geometry,
the rate of drug will always decrease as the concentration gradient
between the tablet surface and environment decreases. However, on the
positive side, when tuning drug release via geometry there is no need to
alter the formulation composition, manufacturing process or equipment
that could signiﬁcantly reduce production cost and time. Simple geo-
metries can easily be produced using traditional manufacturing routes
such as tablet press but this is largely limited by the lack of geometry
ﬂexibility. In comparison 3D inkjet printing oﬀers great geometry
ﬂexibility whilst keeping low marginal costs when design changes are
implemented [32–35]. Moreover, 3D inkjet also provides the potential
to modify the initial distribution of the drug within the tablet, which
can potentially address the issue described above with solely depending
on geometry to control drug release rates. Although, it should be noted
that to simplify matters, this initial study will investigate the eﬀect of
geometry alone, with drug distribution being investigated in future
work.
Hence, the primary objective of this study was to develop a 3D hot-
melt inkjet printing method suitable for fabricating solid dosage forms
with variable complex geometries at high spatial resolution for the
achievement of variable and predictable drug release proﬁles. A sec-
ondary objective was to develop an analytical solution to model the
drug release proﬁle so that the drug release mechanism could be better
understood. Such a model, when developed fully, could in the future be
used to deﬁne the geometry required to produce a clinically required
drug release proﬁle. Honeycomb geometry tablets were printed to de-
monstrate our primary objective. Beeswax, a biocompatible, safe and
FDA approved excipient was used as the drug carrier [36–38]. Beeswax
has been exploited in pharmaceutical formulations, such as nano-
particles for controlled drug delivery [39]. Fenoﬁbrate which is prac-
tically insoluble and is used for the treatment of hypertriglyceridemia,
mixed dyslipidemia and hyper-cholesterolemia was used as an example
drug [40]. This is hence a solvent free process. According to the in-
ternational conference on harmonisation (ICH) guidelines Q3C [41],
only a limited number of solvents meet regulatory requirements due to
toxicological reasons [42]. Therefore this solvent-free 3D inkjet printing
method eliminates the need for a rigorous solvent selection step.
Whilst 3D printing of tablets has been demonstrated previously
using a variety of methods such as extrusion, powder based method and
fused deposition modelling [5,28,43], this work represents a novel
approach to the use of 3DP for dosage form manufacture.
2. Materials and methods
2.1. Materials
White beeswax was kindly donated by Cornelius Group plc
(Stortford, Herts, UK). Fenoﬁbrate, potassium phosphate monobasic
(ACS reagent≥ 99%) and sodium phosphate dibasic were purchased
from Sigma Aldrich, (UK). Sodium lauryl sulphate was purchased from
Fisher Scientiﬁc UK Ltd.
2.2. Preparation and printing of the mixture
A mixture containing 5% w/w fenoﬁbrate was prepared by melting
beeswax (19 g) and fenoﬁbrate (1 g) using a magnetic stirrer hotplate at
90 °C. The melt was immediately transferred to the piezoelectric inkjet
printer (PiXDRO LP50, Meyer Burger) ﬁtted with a hot melt chamber
and a printing head with 128 nozzles (Spectra® SE-128 AA, Fujiﬁlm
Dimatix, Santa Clara, USA). The diameter of the nozzles was 35 μm and
the nozzle spacing was 508 μm. The temperature of the hot melt
chamber and printing head was set at 90 °C to maintain the mixture in
the molten state and to optimize the printability. A ﬁring voltage of
90 V was applied. Printing was done on polyethylene terephthalate
(PET) substrate with a set temperature of 40 °C.
2.3. X-ray micro computed tomography
X-ray micro-CT scanning was performed using a phoenix v|tome|x
m (GE Sensing & Inspection Technologies GmbH, Wunstorf, Germany).
The scanner consisted of a 240 kV microfocus X-ray tube ﬁtted with a
tungsten transmission target and a DXR-250 detector. A maximum X-
ray energy of 65 kV and 130 μA was used to scan each sample. Images
were acquired using a fast scan mode. A total of 2878 projection images
were acquired over a 360° rotation and 250 ms detector exposure time
per projection image. 3-D volumetric data sets were obtained by re-
construction of the projection images using datos|rec software (GE
Sensing & Inspection Technologies GmbH). A volume analyser tool in
VG StudioMAX® 2.2 (Volume Graphics GmbH, Heidelberg, Germany)
was used to visualise the reconstructed CT images.
2.4. Diﬀerential scanning calorimetry (DSC)
Standard DSC measurements were performed with a Q2000 DSC
(TA instruments, Waters, LLC, USA) at a heating rate of 10 °C/min. The
sample mass was between 5 and 10 mg and the analysis was carried out
using hermetically sealed aluminium pans with lids. Calibration was
with indium (Tm = 156.6 °C ± 0.5 °C), ΔHf = 28.71 ± 5% J/g).
Nitrogen was used as a purging gas with a ﬂow rate of 50 mL/min. Data
was collected with TA Advantage software and analysed using TA
Instruments Universal analysis 2000.
2.5. Time of ﬂight – secondary ion mass spectroscopy (ToF-SIMS)
ToF-SIMS analysis was carried out on printed beeswax-fenoﬁbrate
mixture ﬁlms and data was acquired with a ToF-SIMS IV instrument
(ION-ToF GmbH, Germany) equipped with a Bi3+ cluster primary ion
gun and a single-stage reﬂectron mass analyser. A primary ion energy of
25 keV, pulsed target current approximately 1.0 pA were employed.
Due to the non-conductive nature of the samples, charge compensation
was applied in the form of a low energy (20eV) electron ﬂood gun. The
primary ion beam had a focused beam size of 1–2 μm, and the primary
ion dose density was maintained at< 1 × 1012 ions/cm2 throughout to
ensure static conditions. The spectra were acquired over
200 μm× 200 μm areas in both the positive and negative polarity, at a
resolution of 256 pixels × 256 pixels. Each area was scanned 15 times,
using a random raster pattern. The depth proﬁling analysis was per-
formed using a Bi3+ cluster primary ion and the sample was sputtered
using Ar2000+ cluster ions. The two beams were operated in the dual
beam mode. The Ar2000+ sputtering beam (target current of 1.1 nA)
was rastered over the sample area of 400 μm× 400 μm with a spot size
of ∼25 μm and only the central area of the sputtered region
(200 μm) × 200 μm) was then analysed in between the sputtering
pulses. All the ToF-SIMS data acquisition, processing and analysis were
performed using SurfaceLab 6 (ION-TOF) software and the peak
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intensities were normalized to the total ion count of the spectra.
2.6. Raman spectroscopy
Raman spectroscopy was performed using a HORIBA Jobin Yvon
LabRAM HR spectrometer equipped with an automated xyz stage
(Märzhäuser). Spectra were acquired using a 785 nm laser at 25 mW
power, a 50× objective and a 300 μm confocal pinhole. To simulta-
neously scan a range of Raman shifts, a 600 lines/mm rotatable dif-
fraction grating along a path length of 800 mm was employed. Spectra
were detected using a SYNAPSE CCD detector (1024 pixels) thermo-
electrically cooled to −60 °C. Before the spectra collection, the in-
strument was calibrated using the Rayleigh line at 0 cm−1 and a
standard Si (100) reference band at 520.7 cm−1. Raman spectra of the
reference materials (pure beeswax and fenoﬁbrate) were acquired from
100 to 4000 cm−1, with 5 s and 16 accumulations per spectral window.
During mapping, spectra were collected between 860 and 1540 cm−1
across an area of 250 × 250 μm with a grid spacing of 2 μm along both
the x and y axes, a total of 15,876 spectra per map. As each individual
spectrum was collected for 2 s, repeated once in order to automatically
remove spikes due to cosmic rays, the whole map required approxi-
mately 18 h. Component ﬁtting was conducting using the classic least
squares (CLS) regression analysis functionality in Labspec 6.
2.7. In vitro drug release studies
In vitro drug release studies were undertaken using a United States
Pharmacopeia (USP) type 2 apparatus (Dissolution-Erweka Dt600
Dissolution Tester). In each assay the tablet was placed in a vessel
containing 0.1 M phosphate buﬀer (500mls), at pH 7.40, 37 ± 0.5 °C
and the dissolution medium was stirred at 50 rpm. The dissolution
medium also contained 0.05 M sodium lauryl sulphate to facilitate the
wetting process. Samples (5 ml) were withdrawn at hourly intervals for
12 h and a fresh dissolution medium (5 ml) at 37 ± 0.5 °C was re-
placed each time to maintain a constant volume in the dissolution
vessels. All samples were ﬁltered through a 0.45 μm MF-millipore
membrane ﬁlter (MILLEX ®HA) and analysed by a UV–vis spectro-
photometer (DU®800 Series UV/Vis Spectrophotometer, Beckman
Coulter, UK) at 290 nm. All dissolution tests were done in triplicate and
the average of the percentage cumulative drug release as a function of
time was determined.
2.8. Investigating the eﬀect of cell diameter on wetting
The dissolution medium (100 μL) containing 0.1 M phosphate buﬀer
(pH = 7.4) and 0.05 M sodium lauryl sulphate was pipetted con-
tinuously onto a honeycomb tablet (cell diameter = 0.2 mm) sus-
pended on top of an open eppendorf tube to allow the medium to ﬂow
freely through the cells. The time it took for the medium to ﬂow
through the tablet, on ﬁrst application (before wetting) was recorded.
Using the same honeycomb, a fresh medium (100 μL) was pipetted and
the time it took for the medium to ﬂow through the honeycomb on
second application (after wetting) was recorded. The same procedure
was repeated for honeycomb tablets with cell diameters 0.41, 0.61,
1.22 and 1.83 mm. All the honeycombs used in this study had the same
height of 3.22 mm.
3. Results and discussion
3.1. Printed tablets and their physical characteristics
Tablets with honeycomb architecture were printed and the honey-
comb cell diameters were varied between 0.20 mm and 1.83 mm
(Fig. 1a). Diameters larger than 1.83 mm were also explored, however,
beyond this diameter, the honeycomb tablets were relatively fragile and
were deemed unacceptable for normal handling. Conventionally shaped
solid (circularly cylindrical) tablets were also printed for comparison
purposes (cell diameter deﬁned as 0 mm for modelling purposes). Vi-
sually the tablets were well-deﬁned, smooth surfaced and with no ap-
parent defects.
Fig. 1b shows the interior structure of the honeycombs visualised
using micro X-ray computed tomography. The μCT scans show that the
honeycomb tablets had well-deﬁned and ordered honeycomb channels.
Such precision was achieved due to the high spatial resolution attained
via the deposition of very small volumes, in the range of picolitres,
when using the ink jetting technique [44].
Tablets were printed with a constant weight of 100 mg and a ﬁxed
tablet diameter of 10 mm, aimed at maintaining the same drug content.
Due to this restricted tablet diameter and mass, the height of the tablets
varied between 9.73 mm (for the largest cell diameter, 1.83 mm) and
1.98 mm (solid, no cells) (Table 1). This can be explained by the fact
that as the cell size decreases, the number of honeycomb channels
printed (packed) within the restricted diameter increases. As a result, at
smaller cell diameters, tablets were printed with relatively reduced
height but the same weight as tablets with larger cell diameter.
In the case of the honeycomb geometry, the open honeycomb
channels provide a path for the dissolved drug, the length of the
channels will therefore aﬀect the drug delivery surface area (SA) and
hence the rate of drug release. In order to investigate this eﬀect a batch
of tablets was printed with the length of the channels ﬁxed by printing
tablets with constant height of 3.22 mm, which is a comparable height
to tablets on the market. When the tablet height was ﬁxed, the SA/V
ratio (where volume, V, is proportional to mass of drug with a ﬁxed
concentration) of the honeycomb like tablets increased in a controlled
manner with decrease in cell diameter (Table 2). It was noted that the
honeycomb cell diameters of the printed tablets did not diﬀer sig-
niﬁcantly from the diameters in the geometry design speciﬁcation. The
geometrical properties of the printed tablet with constant mass and
height are shown in Tables 1 and 2 respectively.
3.2. Diﬀerential scanning calorimetry
The DSC thermograms obtained for fenoﬁbrate, beeswax, and the
printed mixture with 5% w/w fenoﬁbrate are shown in Fig. 2. Fenoﬁ-
brate thermogram (red) presented a sharp endotherm at 81.4 ± 0.2 °C,
consistent with the distinctive melting point previously observed for
Form I, which is the most stable crystalline form compared to the me-
tastable Forms II and III [45–47]. The beeswax thermogram (blue)
showed a broad peak, with complete melting occurring at
63.0 ± 0.1 °C. In addition polymorphic phase transitions between
40 °C and 50 °C were observed in the beeswax thermogram. The ob-
served beeswax thermogram trace was in relatively good agreement
with data reported in the literature [48,49].
Beeswax is comprised of a mixture of two amorphous crystalline
states [50,51]. Hydrocarbon molecules and monoesters crystallise to
form orthorhombic structures, whilst the free acids and diesters form a
monoclinic structure [50,51]. A phase transition from orthorhombic to
a rotator phase has been reported to occur at approximate at 36.4 °C
[52]. Also, Kameda et al. reported a conformational transformation
between 42 °C and 50 °C [49]. The thermogram trace obtained for the
printed mixture containing 5% w/w fenoﬁbrate (purple) was very si-
milar to that observed for beeswax, no sharp melting peak for the
crystalline fenoﬁbrate Form I was observed, suggesting that the drug is
presented in an amorphous state completely miscible within the
beeswax, at least to the sensitivity limit of the DSC. In this work, for-
mulation analysis was carried out immediately after printing, therefore
stability was not an issue. For drug quality and patience safety reasons,
the stability of a drug product must be well understood [53]. With this
in consideration, drug stability of these formulations is a key subject for
our future work.
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3.3. Time of ﬂight – secondary ion mass spectroscopy surface and depth
analysis
In order to understand if the drug was evenly distributed, the mi-
croscale distribution of the drug in the beeswax matrix was in-
vestigated. Firstly spatial mapping of the drug at the upper most surface
(1–2 nm) and within the bulk (near surface) as a function of depth was
achieved using ToF-SIMS. Positive and negative ToF-SIMS spectra were
acquired. The negative spectra showed characteristic ion-fragment
peaks for the fenoﬁbrate ion C13H8ClO2− at m/z= 231 and for
beeswax at m/z= 367 (Fig. 3a). ToF-SIMS images were retrospectively
reconstructed to assess the spatial distribution of the C13H8ClO2− ion in
the XY coordinate (Fig.3b) and YZ coordinate (Fig. 3c). The XY data in
Fig. 3b showed that at the micro-scale level, the fenoﬁbrate fragment
ion (C13H8ClO2−) was heterogeneously distributed at the surface. Such
microscale localization of a drug is not uncommon in dispersions of
drugs in pharmaceuticals [54].
Fig. 3c illustrates a clear contrast between the upper most surface,
with relatively lower drug ion intensity, and the bulk (near-surface),
with higher ion intensity. As shown in Fig. 3d, the intensity of drug ion
Fig. 1. a) Photographs of the printed solid tablet and hon-
eycomb -like tablets with varying cell sizes between
0.20 mm and 1.83 mm. b) 3D μCT scan images obtained for
the honeycomb architecture tablets, the right hand image
has a digital cut-away.
Table 1
Geometric properties of tablets printed (with constant weight = 100 mg).
Geometry Digital
design cell
diameter
[mm]
Printed tablet
cell diameter
[mm]
Tablet height
[mm]
Tablet
surface
area
[mm2]
SA/V
ratio
Honeycomb 1.827 1.78 ± 0.08 9.73 ± 0.029 1821 5.25
Honeycomb 1.218 1.17 ± 0.03 7.61 ± 0.01 1970 5.30
Honeycomb 0.609 0.62 ± 0.01 4.82 ± 0.08 2045 5.87
Honeycomb 0.406 0.34 ± 0.02 3.27 ± 0.04 2410 7.07
Honeycomb 0.203 0.19 ± 0.01 2.01 ± 0.04 2108 5.80
Solid tablet 0 0 1.98 ± 0.02 219 1.41
Table 2
Geometric properties of printed tablets (with constant height = 3.22).
Geometry Digital
design cell
diameter
[mm]
Printed tablet
cell diameter
[mm]
Tablet
surface
area
[mm2]
Tablet diameter
[mm]
SA/V
ratio
Honeycomb 1.827 1.78 ± 0.08 624 10.13 ± 0.03 5.44
Honeycomb 1.218 1.17 ± 0.03 870 10.12 ± 0.03 6.26
Honeycomb 0.609 0.62 ± 0.01 1574 10.12 ± 0.03 6.76
Solid tablet 0 0 258 10.12 ± 0.03 1.02
Fig. 2. DSC thermograms for fenoﬁbrate (red), beeswax (blue) and printed mixture
containing 5% w/w fenoﬁbrate (purple). (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)
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increased with increase in depth (over a depth of approximately
2.5 μm) and then became constant, suggesting a uniform distribution of
the drug ion beyond the immediate surface and therefore for the vast
bulk of the tablet. It is anticipated that the depletion of drug at the very
surface is due to the formation of crystalline regions of beeswax systems
at the surface which occurs during the cooling process (Fig. SI-1). This
is typically termed as an eﬄorescence phenomenon and becomes more
apparent in the presence of impurities, in this case drug particles
[55,56]. The drug is excluded from the crystalline regions leading to the
observed uneven distribution of the drug at the surface. Longer-term
stability studies beyond the remit of this work are required to assess
whether the microscale heterogeneity observed at the surface inﬂu-
ences the physical instability and crystallisation of the drug, an im-
portant consideration when developing commercial dosage forms.
3.4. Raman spectroscopy
Raman spectroscopy was used to gain further understanding of drug
distribution. The beeswax Raman spectrum (Fig. 4a) contains promi-
nent vibrational modes at 1063 (ν(CC) stretch), 1131 (δ(CH) chain
deformations), 1296 (δ(CH2)2 deformation), ~1440 (δ(CH2) deforma-
tions) and ~2880 cm−1 (ν(CH) stretches), consistent with the complex
composition of beeswax of various saturated and unsaturated hydro-
carbons, esters and free fatty acids, including the known major com-
ponent triacontanyl palmitate, and is analogous to previous literature
reports [57]. The Raman spectrum obtained for fenoﬁbrate (Fig. 4a)
contains numerous bands in the ﬁngerprint region and CH stretching
regions with diagnostic vibrational modes at ~1590 cm−1 (ν(C]C) in-
plane aromatic ring stretches) and 1650 cm−1 (ν(C]O) stretch). The
Raman spectrum obtained for the printed beeswax-fenoﬁbrate mixture
(Fig. 4a), collected at a single random location, was comprised of a
superposition of both beeswax and fenoﬁbrate, dominated by the vi-
brational modes of beeswax consistent with its higher concentration in
the formulation, with no signiﬁcant shifts in the position of the com-
ponent bands in the mixture relative to the isolated components, in-
dicating little to no structural changes to either beeswax or fenoﬁbrate
upon mixing and subsequent printing.
Furthermore, Raman spectroscopic mapping across an area of
250 μm× 250 μm of the printed mixture and subsequent chemometric
data analysis (Fig. 4b) showed that fenoﬁbrate was uniformly dis-
tributed in the bulk (red colour 4–6% of the total composition of the
mixture variable as a function of speciﬁc location by classic least
squares regression analysis within the beeswax (blue). It is important to
note that the penetration depth of the laser is of the order of ~20 μm
Fig. 3. ToF-SIMS data. a) ToF-SIMS mass spectrum for the printed beeswax-fenoﬁbrate mixture b) ToF-SIMS chemical map showing the distribution of the fenoﬁbrate fragment ion
(C13H8ClO2−) at the surface in the XY coordinate. c) ToF-SIMS chemical map showing the distribution of C13H8ClO2− in the YZ coordinate. d) ToF-SIMS depth proﬁle showing the
increase in the intensity of C13H8ClO2− (red) as a function of depth. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
Fig. 4. Raman spectroscopy a) Beeswax Raman spectrum
(blue), fenoﬁbrate Raman spectrum (red), and the printed
mixture containing 5% fenoﬁbrate (purple). Spectra have
been oﬀset on the y-axis for clarity. b) A Raman map
showing the uniform distribution of fenoﬁbrate (red)
within the beeswax matrix (blue) in the XY coordinate. (For
interpretation of the references to colour in this ﬁgure le-
gend, the reader is referred to the web version of this ar-
ticle.)
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and thus the displayed chemical map is more representative of the
underlying bulk, rather than the surface structure. Therefore Raman
spectroscopy and ToF-SIMS depth proﬁle data provide complementary
evidence for the uniform distribution of the drug within the bulk of the
printed structure.
Fig. 4b provided evidence that at this micron scale, the drop like
deposition of material used in 3DP was retained to an extent in the
micro-scale architecture of the tablet surface.
3.5. In vitro drug release studies
All the printed tablets contained 5% w/w fenoﬁbrate, chosen on the
basis of drug release performance. Mixtures with higher drug loading
(10–25% w/w) were also printed without compromising geometry, but
higher drug loading resulted in relatively slower drug release (Fig. SI-
2). This suggests that some of the drug is in its crystalline state at these
higher loadings, a commonly observed phenomena in the attempted
formation of solid dispersions at higher drug loadings. Some authors
have suggested that at such high drug loadings, the dissolution per-
formance is mainly governed by the physicochemical properties of the
drug (low aqueous solubility and hydrophobicity) [58,59]. The release
of fenoﬁbrate from printed tablets into 500 mL of phosphate buﬀer at
pH 7.40, and 37 °C is illustrated in Fig. 5a. The honeycomb tablets
showed higher release rates in comparison to the solid tablet, attributed
to the increase in the surface area associated with the geometry. The
change in the release proﬁle due to geometry modiﬁcation from solid
(circular disk) to the honeycomb geometry clearly shows the potential
to manipulate and deﬁne drug release proﬁles. In the case of the hon-
eycombs, the mass of the tablet and the thickness of the walls were kept
constant but the cell diameter and the height of the tablets were varied.
As shown in Fig. 5a, honeycombs with cell diameters ≥0.41 mm
showed similar release proﬁles, but the optimum (greatest) release was
obtained with a cell diameter of 0.61 mm. Since a key variable in de-
termining the drug release rate is the available surface area, it was
expected that reducing the cell diameter would show an increase in the
release rate. However, the release proﬁle obtained for the honeycomb
with the smallest cell diameter (0.20 mm) was slower than expected
and substantially below that observed for tablets with signiﬁcantly
lower surface area/volume ratios. This is proposed to be due to the
eﬀect of poor wetting through the relatively hydrophobic beeswax
channels of the smaller pores.
To assess this proposed poor wetting eﬀect, the average time for
100 μL of the dissolution medium to ﬂow through the honeycomb ta-
blets on ﬁrst application (before wetting) and a second application
(after wetting) was determined and this is illustrated in Fig. 5b. It was
observed that below a certain size (< ca. 0.5 mm), the cell diameter
Fig. 5. In vitro release studies and prediction of drug release. a) Dissolution proﬁles for the printed solid tablet and honeycomb like tablets with constant weight. b) A graph showing the
average time for the dissolution medium to penetrate through the honeycomb tablet as a function of cell diameter. c) Eﬀect of surface area to volume ratio on drug release. d) Honeycomb
geometry applied to predict the theoretical release proﬁles. e) A ﬁt of the numerical model to the experimental dissolution proﬁles for three tablets of cell diameters 0.6, 1.2 and 1.8 mm.
f) Predicted dissolution proﬁles resulting from variation of cell diameter from 0.5 to 2.5 mm in steps of 0.5 mm. The legend refers to the cell diameters. g) Predicted dissolution proﬁles
resulting from variation of the honeycomb wall thicknesses through the values 0.05, 0.075, 0.1, 0.2 and 0.3 mm. The legend refers to the honeycomb wall thicknesses.
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inhibited wetting. The speed of ﬂow (wetting) remained approximately
constant until this critical cell diameter was reached. In comparison to
the other honeycombs, the rate of ﬂow through the honeycomb tablet
with the smallest diameter (0.2 mm) was signiﬁcantly reduced and this
was more noticeable before wetting. Based on this observation it was
inferred that when dry honeycomb tablets with very small cell dia-
meters (< ca. 0.5 mm) are immersed in a dissolution media, it takes
longer to completely wet their surfaces. For this particular honeycomb
architecture, the observed wetting eﬀect is consistent with the reduc-
tion in the release rate despite the increase in surface area in the case of
smaller cell sizes (0.2 mm and 0.4 mm). It should be noted that the SA/
V for the honeycomb tablet with cell diameter of 0.2 mm was lower
than expected. This is attributed to the reduction in the accuracy of the
printed geometry (due to the distortion of the hexagonal shape of the
cells) which was observed at this smallest cell diameter (Fig. SI-3). This
clearly indicates a lower limit of cell size for structural integrity for this
material and printer combination.
3.6. Eﬀect of geometry (surface area/volume ratio) on drug release
Fig. 5c shows the eﬀect of surface area to volume ratio (SA/V) on
drug release. The investigation was carried out using honeycomb like
tablets with a cell diameter above the established critical cell diameter
(ca. 0.5 mm). In this study, the height of the honeycombs tablets and
the thickness of the cell wall were ﬁxed and the surface area to volume
ratio was increased uniformly via a decrease in cell diameter. The rate
of drug release increased as expected with increasing SA/V in the order
of cell diameter 0.61 > 1.12 > 1.83 mm. This evidence demonstrates
that geometry can be used to control the release proﬁle but geometry
conﬁgurations must be carefully selected. For the honeycomb geo-
metry, it appears that both the cell diameter and surface area to volume
ratio play a signiﬁcant role, but if the cell diameter is suﬃciently large
enough to allow a signiﬁcant rate of ﬂow of the dissolution medium,
SA/V becomes the controlling variable.
3.7. Drug release mechanism and prediction of drug release
In vitro release data obtained for the honeycomb tablet with the
highest drug release (0.61 mm) was ﬁtted to ﬁrst order, Higuchi [60],
and Korsmeyer-Peppas kinetic models [61] using Microsoft excel 2013.
The most signiﬁcant ﬁt to the data was observed with Korsmeyer-
Peppas model (Eq. (1)), with R2 = 0.98 and exponent n= 0.31 (Fig. SI-
4). A study of dependent variables from a full factorial design to cal-
culate degrees of freedom [62] was not carried out in this work,
nevertheless the use of R2 as a useful guide is not uncommon in the
literature [63].
=
∞
M
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where Mt/M∞ is a fraction of drug released at time t, K is the release
rate constant and n is related to the diﬀusion mechanism. Additionally
it was observed that the tablets remained intact during the dissolution
studies, with no observable swelling or change in shape or size occur-
ring during the dissolution studies. These observations suggest a Fickian
diﬀusion controlled drug release mechanism, as has previously been
observed for similar non-degrading matrices [64].
In order to illustrate how control over geometry can elucidate
control over dissolution and enable an element of personalisation, a
model was constructed to show how dissolution will vary in relation to
changes in key geometrical parameters. This model was aided by the
Korsmeye-Peppas ﬁt which indicated diﬀusion controlled dissolution,
allowing the model to be limited to Fickian diﬀusion models only. The
geometry of the honeycomb tablets was approximated by treating it as a
composite of semi-inﬁnite plates, with second order corrections to ac-
count for overlaps at the joins of intersecting struts (i.e., accom-
modating small reductions in the area available for the drug to elute
from). This approach is rather attractive, since it allows the use of
analytical predictions of drug release, and thus the model consists of a
summation of widely known and well understood solutions [65] given
by.
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for a single slab, where Mt and M∞ denote the cumulative amounts of
drug released at time t and at inﬁnite time, respectively; D is the dif-
fusion coeﬃcient of the drug within the matrix, L is the thickness of the
slab and n is a dummy variable to allow summation. The unknown
inputs to this model, the diﬀusion coeﬃcient and proportion of drug
able to release from the tablet (i.e., D and M∞), were then used as
coeﬃcients for a non-linear curve ﬁtting exercise using the intrinsic
Matlab function, nonlinlsq, enabling us to identify D and M∞ for each
tablet tested. This was performed for three tablets, from which the
average diﬀusion coeﬃcient was determined as
D = 3.6 ± 0.7 × 10−7 mm2·s−1 and the average proportion of drug
released as 0.78 ± 0.05. As can be observed from Fig. 5e the ﬁts are
close, giving conﬁdence that such a method can capture the main fea-
tures of the drug dissolution.
To further understand the mechanisms at work here, the model was
then used to predict dissolution trends when varying the cell diameter
(and thus number of cells) and the honeycomb wall thickness. The
average diﬀusion coeﬃcient and proportion released determined above
were employed. First, using the same structure as that employed for
honeycombs in Fig. 5a, the cell diameter was systematically varied from
0.5 to 2.5 mm in steps of 0.5 mm, noting that a cell diameter of 2.5 mm
is around 50% of the total tablet diameter. In this case it was seen that
as the cell diameter increased, the dissolution rate reduced. This can be
interpreted by viewing the tablet in two parts – the honeycomb and the
shell. Increasing cell diameter reduces the number of cells, making the
system more dependent on the properties of the shell. In this case, the
shell thickness is relatively thick and thus, the dissolution slows down
(Fig. 5f). The model shows that if the shell thickness is made very small,
the dissolution becomes invariant with respect to the cell diameter or
the number of cells, since the surface area will scale directly with the
volume of drug available (Figure not shown). Secondly, the honeycomb
wall thickness was increased to give thicknesses of 0.05, 0.075, 0.1, 0.2
and 0.3 mm. Here the dissolution trends are not so simple (Fig. 5g).
When the honeycomb wall thicknesses are small the release is initially
fast, but then it transitions to a slower release as the drug in the hon-
eycomb is depleted but drug in the shell continues to elute, but at a
slower rate due to the relatively longer diﬀusion path in the shell
compared to the honeycomb walls. As the honeycomb thickness is in-
creased, the period of fast release is extended until the point when the
honeycomb thickness is appreciable and the dissolution proﬁle takes on
the appearance of a single smooth release.
These observations indicate that through manipulation of the shell
thickness, honeycomb wall thickness and the number of cells, it is
possible to operate within a window of release rate that approaches a
factor of 4 from slowest to fastest, whilst additionally being able to vary
the dose independently by changing the height of the tablet.
The predictions from this model demonstrate how the coupling of
geometrical freedom enabled by 3D printing and predictive phenom-
enological modelling could ultimately provide an opportunity to pro-
duce a tablet (or indeed any solid delivery vehicle, e.g. drug loaded
implant) with a pre-determined release proﬁle. Together with the op-
portunities 3DP provides for personalised drug loading and controlled
drug distribution within a dosage form, which will potentially expand
the window of drug release proﬁles beyond that available with geo-
metrical control alone, we believe that further development of the ap-
proaches described in this paper will enable signiﬁcant, new clinical
opportunities.
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4. Conclusions
In summary, for the ﬁrst time, it has been shown that drug loaded
solid dosage forms with complex geometries can be manufactured using
hot-melt 3D inkjet printing and that variation in drug release proﬁles
can be obtained in a controllable manner by combining the geometrical
capability of 3D printing with predictive computational approaches.
This has implications for controlled release from solid dosage form to
support a particular treatment regime. It has been established that
geometric parameters such as the cell diameter in the case of honey-
comb geometry can be used predictably to alter release, as long as other
inﬂuencing factors (in this case wettability) are accounted for.
Modelling the release proﬁles of the honeycomb geometry as a sum of
the release proﬁles of its constituent slabs is a promising strategy to
facilitate the selection of geometries with suitable conﬁguration. The
purpose of this work was not to suggest that the honeycomb geometry is
optimal for tablets but to demonstrate the freedom aﬀorded by varying
the geometry on the control of drug release. It is anticipated that the
development of this technique could provide an alternative manu-
facturing route for solid dosage forms with geometry ﬂexibility and
complexity suited for advanced drug delivery. Such geometries could,
for example, be manipulated to achieve release proﬁles for personalised
medicines or as a generic platform for diﬀerent drugs, without the need
to change the basic formulation composition, the processing parameters
or the manufacturing equipment. It is further indicated that the ink jet
technique is ideal for printing tablets with highly controlled distribu-
tions of drug (or multiple drugs) within a complex geometry, which will
further expand the window for designed drug delivery.
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